- Home
- DNP vs RYTM Comparison
DNP vs RYTM Comparison
Compare DNP & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- RYTM
- Stock Information
- Founded
- DNP 1986
- RYTM 2008
- Country
- DNP United States
- RYTM United States
- Employees
- DNP N/A
- RYTM N/A
- Industry
- DNP Investment Managers
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- DNP Finance
- RYTM Health Care
- Exchange
- DNP Nasdaq
- RYTM Nasdaq
- Market Cap
- DNP 3.6B
- RYTM 3.8B
- IPO Year
- DNP N/A
- RYTM 2017
- Fundamental
- Price
- DNP $9.72
- RYTM $68.11
- Analyst Decision
- DNP
- RYTM Strong Buy
- Analyst Count
- DNP 0
- RYTM 12
- Target Price
- DNP N/A
- RYTM $76.75
- AVG Volume (30 Days)
- DNP 531.8K
- RYTM 592.0K
- Earning Date
- DNP 01-01-0001
- RYTM 08-05-2025
- Dividend Yield
- DNP 8.04%
- RYTM N/A
- EPS Growth
- DNP N/A
- RYTM N/A
- EPS
- DNP 2.28
- RYTM N/A
- Revenue
- DNP $155,280,425.00
- RYTM $136,863,000.00
- Revenue This Year
- DNP N/A
- RYTM $37.56
- Revenue Next Year
- DNP N/A
- RYTM $74.99
- P/E Ratio
- DNP $4.25
- RYTM N/A
- Revenue Growth
- DNP 10.15
- RYTM 48.88
- 52 Week Low
- DNP $8.02
- RYTM $38.85
- 52 Week High
- DNP $10.04
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- DNP 51.79
- RYTM 64.14
- Support Level
- DNP $9.67
- RYTM $63.90
- Resistance Level
- DNP $9.79
- RYTM $63.24
- Average True Range (ATR)
- DNP 0.10
- RYTM 2.42
- MACD
- DNP -0.02
- RYTM 0.59
- Stochastic Oscillator
- DNP 36.54
- RYTM 98.48
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.